Emami Q1FY26: Domestic Sales Surge 20%, Volume Grows 8% Amid Profit Dip
Emami posted a 15.4% decline in consolidated net profit to ₹1,389.40 lacs in Q1FY26, even as revenue from operations rose 15% to ₹1,039.21 lacs. Domestic sales surged 20% (12% like-for-like) with 8% volume growth. Higher tax expenses and acquisition-related costs weighed on profitability, while strategic acquisitions of Axiom Ayurveda and IncNut Digital expanded the company's portfolio.

*this image is generated using AI for illustrative purposes only.
Emami reported a mixed performance for the first quarter of FY26 (ended June 30, 2026), with consolidated net profit declining 15.4% year-on-year to ₹1,389.40 lacs, while revenue from operations grew 15% to ₹1,039.21 lacs. Domestic sales increased by 20%, with a 12% growth on a like-for-like basis, and the company recorded a volume growth of 8% for the quarter. The Board of Directors approved the unaudited financial results on August 4, 2026. The decline in profitability despite top-line growth was driven by higher tax expenses and the integration costs associated with recent acquisitions, including Axiom Ayurveda Private Limited and IncNut Digital Private Limited.
Financial Performance
The company's consolidated revenue from operations stood at ₹1,039.21 lacs for Q1FY26, up from ₹904.09 lacs in the corresponding quarter of FY25. Other income decreased to ₹18.50 lacs from ₹21.59 lacs. Total income for the quarter was ₹1,057.71 lacs.
Consolidated EBITDA rose marginally to ₹2,446.80 lacs from ₹2,358.10 lacs year-on-year. However, the EBITDA margin contracted to 23.54% from 26.08%. Finance costs increased significantly to ₹5.61 lacs from ₹2.43 lacs. Depreciation and amortization expenses remained relatively stable at ₹42.76 lacs. The following table summarizes the key consolidated financial metrics for the quarter:
| Metric | Q1FY26 (₹ Lacs) | Q1FY25 (₹ Lacs) | Change |
|---|---|---|---|
| Revenue from Operations | 1,039.21 | 904.09 | +15.0% |
| EBITDA | 2,446.80 | 2,358.10 | +3.8% |
| Net Profit After Tax | 1,389.40 | 1,642.60 | -15.4% |
| EPS (Basic) | ₹3.15 | ₹3.76 | -16.2% |
The total tax expense for the quarter was ₹55.77 lacs, compared to ₹22.51 lacs in Q1FY25. This increase was partly due to the utilization of Minimum Alternate Tax (MAT) credit. The company utilized ₹13.45 lacs of MAT credit during the quarter, bringing the remaining MAT credit balance to ₹604.92 lacs as of June 30, 2026.
Operational Highlights
Emami's domestic business demonstrated strong momentum during the quarter, with domestic sales rising 20% overall and 12% on a like-for-like basis, reflecting underlying demand strength. The company also recorded a volume growth of 8% for Q1FY26, indicating healthy consumer offtake across its product portfolio.
Strategic Acquisitions
Emami expanded its portfolio through two significant acquisitions during the quarter. On April 1, 2026, the company acquired a controlling stake in Axiom Ayurveda Private Limited by paying a first tranche consideration of ₹100 crores towards a total agreed consideration not exceeding ₹200 crores. This transaction converted Axiom into a subsidiary, and its financial results have been consolidated from April 1, 2026.
Additionally, on June 1, 2026, Emami acquired a 60% controlling stake in IncNut Digital Private Limited for a consideration of ₹320.99 lacs under a Share Subscription and Purchase Agreement dated May 7, 2026. The remaining 40% shareholding will be acquired through subsequent tranches over the next four years. Both acquisitions were accounted for as business combinations under IND AS 103, making the current quarter's financials not directly comparable with previous periods.
Auditor's Qualified Conclusion
S.R. Batliboi & Co. LLP, the statutory auditors, issued a qualified conclusion on the consolidated financial results. The qualification arises because the interim financial results of certain subsidiaries and associates were not reviewed by their respective component auditors. Specifically, the results of one subsidiary group (revenue ₹80.20 lacs, net profit ₹5.32 lacs), another subsidiary group (revenue ₹14.69 lacs, net loss ₹0.92 lacs), and two associates (group share of net loss ₹1.55 lacs) were included based on management-provided unaudited figures. The auditors stated they are unable to comment on the potential financial impact if these entities had been reviewed.
Standalone Results
On a standalone basis, Emami reported a net profit of ₹1,822.20 lacs for Q1FY26, an increase from ₹1,630.90 lacs in Q1FY25. Standalone revenue from operations grew 3.1% to ₹779.92 lacs from ₹756.46 lacs. Standalone EBITDA improved to ₹2,686.20 lacs from ₹2,214.80 lacs. The standalone tax expense was ₹51.38 lacs, including ₹13.45 lacs of MAT credit utilization.
Historical Stock Returns for Emami
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.34% | -5.23% | -6.57% | -18.76% | -35.82% | -30.37% |
How will the integration of Axiom Ayurveda and IncNut Digital impact Emami's EBITDA margins in the subsequent quarters as one-time costs stabilize?
What is the timeline for Emami to acquire the remaining 40% stake in IncNut Digital, and how might this affect future capital allocation strategies?
Given the auditor's qualified conclusion regarding unaudited subsidiary figures, what steps will management take to ensure full compliance and transparency in upcoming financial reports?


































